Fundz
You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →

Saol Therapeutics secures up to $115 million from Oaktree to support the launch preparation for SL1009. The funding will also aid in lifecycle expansion into Congenital Lactic Acidosis and other pain indications.

PRIVATESep 15, 2026•1 day ago

Amount Raised

$115 Million

Round Type

Venture - Series Unknown

BiotechnologyHealth CareScience And Engineering

Investors

Oaktree

Description

Saol Therapeutics has announced a definitive agreement for an investment of up to $115 million from Oaktree. This milestone-based capital will fund the launch readiness for SL1009 and support further development of their portfolio. Additional funds will be released as Saol meets specified regulatory, clinical, and commercial milestones. The financing exemplifies Oaktree's understanding of Saol's long-term potential across its portfolio.

Company Information

Company

Saol Therapeutics

About

Saol Therapeutics (pronounced "Sail") is a privately held, biopharmaceutical company with operations in Roswell, GA, Dublin, Ireland and Hamilton, Bermuda. Saol is focused on commercial and clinical development activity in central nervous system disorders such as spasticity, pain management, and orphan diseases. Saol has a robust pipeline of novel, mid-to-late stage development programs in osteoarthritis, focal spasticity and pyruvate dehydrogenase complex deficiency (PDCD). For more information, visit www.saolrx.com.

Don't miss Saol Therapeutics's next move

Get an email the moment Saol Therapeutics raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Saol Therapeutics's next move

See what Strategic adds

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Saol Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.